119-SJRES-155 Investigative Journalist Impact Analysis

Summary

What the resolution does. S.J.Res. 155 uses the Congressional Review Act (CRA) to disapprove the CFPB’s interpretive rule “Fair Credit Reporting Act; Preemption of State Laws” (90 Fed. Reg. 48710, Oct. 28, 2025). Disapproval would void that rule and prevent the Bureau from issuing a future rule “substantially the same,” absent new statutory authorization. (govinfo.gov)

Regulatory/legal backdrop. The CFPB’s 2025 interpretive rule replaced a 2022 CFPB interpretation that framed FCRA preemption as narrow; it was issued after the Bureau withdrew the 2022 guidance in May 2025. Separately, a district court in July 2025 vacated the Bureau’s distinct Regulation V “medical debt” final rule. Thus S.J.Res. 155 targets preemption guidance, not the already‑vacated medical‑debt regulation. (govinfo.gov)

High‑level impacts. Disapproval would reinforce space for states to restrict reporting and/or use of certain data (notably medical debt). Evidence indicates medical collections are error‑prone and weakly predictive for underwriting, so consumer credit access for affected groups likely improves; industry, however, loses federal uniformity and faces higher compliance and litigation costs under a patchwork regime. (consumerfinance.gov)

Economic Effects

Who gains, who pays, and what could shift in markets if the preemption rule is disapproved.

• Lenders/credit markets: Less uniformity in what appears on reports (e.g., medical debt restrictions in multiple states) can raise compliance, legal, and model‑maintenance costs. The 2025 rule’s preamble argued preemption avoids a “patchwork,” a benefit that would be foregone under CRA disapproval. (govinfo.gov)
• Underwriting accuracy: Multiple CFPB studies and score‑model statements find medical collections have limited predictive value for repayment; removing them can raise scores without materially degrading risk separation, especially as newer FICO/VantageScore versions already down‑weight or exclude medical collections. (consumerfinance.gov)
• Consumer credit access/costs: When medical collections are removed (by bureau policy or state law), average scores rise about 25 points after the last medical collection drops, which can broaden access and lower borrowing costs for many borrowers with past medical bills. (consumerfinance.gov)
• Credit reporting agencies/furnishers: Disapproval sustains state variability over content/use rules (e.g., medical debt, certain criminal records), increasing operational complexity and potential exposure to state enforcement. Industry groups have highlighted such preemption concerns. (library.nclc.org)
• Macro exposure: CFPB estimated $88B of medical bills on credit reports in 2021; policies limiting such data chiefly reallocate costs (compliance, model refreshes) rather than imposing clear macro growth effects. (consumerfinance.gov)

Social Effects

Distributional consequences, communities affected, and data‑integrity concerns.

• Distributional impacts: Medical collections are more prevalent in lower‑income and majority Black/Hispanic census tracts; policies that reduce their credit‑report presence confer relatively larger benefits to these groups, though not uniformly. (consumerfinance.gov)
• Housing and employment screening: Credit‑report content can affect rental approvals and some employment uses; curbing error‑prone medical tradelines may reduce adverse decisions driven by billing inaccuracies. (consumerfinance.gov)
• Data integrity/fairness: The CFPB has documented accuracy problems in medical billing and collections reporting; retaining state authority can reinforce consumer protections aimed at inaccurate or coercive reporting practices. (consumerfinance.gov)
• State authority vs. federal uniformity: Recent appellate decisions (e.g., First and Ninth Circuits) read key FCRA preemption clauses narrowly, supporting room for state consumer‑protection laws; CRA disapproval would align with that judicial trend. (law.justia.com)

Environmental Effects

Does this policy move the emissions or resource‑use needle?

Direct environmental effects are negligible: the measure concerns preemption guidance for credit reporting, not physical infrastructure, land use, or pollution controls. No credible evidence indicates material environmental impacts.

Temporal Analysis

Short‑term versus long‑term consequences and path‑dependence.

1. Immediate (0–6 months): Little operational change because the 2025 rule is guidance without binding effect; its disapproval mainly removes a pro‑preemption signal while leaving courts to decide preemption case‑by‑case. (govinfo.gov)
2. Near term (6–24 months): States are more likely to sustain or expand limits on reporting/using medical debt; lenders/CRAs refine state‑specific workflows and scoring cutoffs; more litigation over FCRA preemption boundaries likely. (library.nclc.org)
3. Long term (2+ years): Persistent state variability becomes the default absent new federal legislation; score models continue de‑emphasizing medical collections, and access expands for consumers with medical debt while industry bears higher compliance/monitoring costs. (vantagescore.com)

Note on related rule: The separate 2025 CFPB medical‑debt Regulation V rule was vacated by a federal court; S.J.Res. 155 does not restore that rule but would bar the Bureau from re‑issuing “substantially the same” preemption interpretation. (consumerfinance.gov)

Unintended Consequences

Risks and side effects documented in credible sources.

• Regulatory uncertainty: Because CRA does not define “substantially the same,” agencies may avoid clarifying guidance even when markets seek it; ambiguity shifts costs to courts and firms. (congress.gov)
• Patchwork compliance: Without a federal preemption signal, multi‑state lenders/CRAs face divergent state mandates on furnished and reported items (e.g., medical debt, certain criminal records), increasing system complexity and potential for inconsistent consumer outcomes. (govinfo.gov)
• Potential for forum shopping: Divergent state standards can incentivize litigants to select favorable venues, increasing defense costs and uneven enforcement pressure. (Analytical inference grounded in the above patchwork and litigation‑trend sources.) (govinfo.gov)

Assessment

Bottom‑line, non‑advocacy judgment from a forensic perspective.

Favorable, unfavorable, or neutral? Neutral. Disapproval would likely enhance state consumer‑protection latitude and improve access for borrowers with medical debt—consistent with empirical findings on limited predictive value—while reducing federal uniformity and increasing compliance/litigation costs for lenders/CRAs. Policymakers face a clear trade‑off between national consistency and state‑level protections/data‑integrity aims. (consumerfinance.gov)

Sourcing (selected)

Key documents underpinning this analysis.

• CFPB interpretive rule, Fair Credit Reporting Act; Preemption of State Laws (90 Fed. Reg. 48710, Oct. 28, 2025). (govinfo.gov)
• GovInfo page for S.J.Res. 155 (text and status). (govinfo.gov)
• CRS, The Congressional Review Act: Frequently Asked Questions (scope and “substantially the same”). (congress.gov)
• CFPB, Consumer Reporting (Regulation V) page noting July 2025 vacatur of the medical‑debt rule. (consumerfinance.gov)
• CFPB research and press materials on medical‑debt predictiveness and score impacts. (consumerfinance.gov)
• Equifax/Experian/TransUnion joint release (medical collections under $500 removed). (investor.equifax.com)
• NCLC analysis summarizing state medical‑debt reporting bans (approx. 15 states). (library.nclc.org)
• Appellate decisions on FCRA preemption boundaries (First and Ninth Circuits). (law.justia.com)
• Congress.gov Executive Communication acknowledging submission of the CFPB preemption rule to the Senate (CRA prerequisite). (congress.gov)